Article Text

other Versions

PDF
Do all anti-citrullinated protein/peptide antibody (ACPA) tests measure the same? Evaluation of discrepancy between ACPA tests in RA and non-RA patients.
  1. Bert Vander Cruyssen (bert.vandercruyssen{at}ugent.be)
  1. UZ Gent, Belgium
    1. Leonor Nogueira (nogueira.l{at}chu-toulouse.fr)
    1. UMR 5165 "Laboratory of Epidermis Differentiation and Rheumatoid Autoimmunity", France
      1. Jens Van Praet (jens.vanpraet{at}ugent.be)
      1. Ghent university hospital, Belgium
        1. Dieter Deforce (dieter.deforce{at}ugent.be)
        1. Laboratory of Pharmaceutical Biotechnology, Ghent University, Belgium
          1. Dirk Elewaut (dirk.elewaut{at}ugent.be)
          1. University Hospital Gent, Belgium
            1. Guy Serre (serre.sec{at}chu-toulouse.fr)
            1. UMR 5165 "Laboratory of Epidermis Differentiation and Rheumatoid Autoimmunity", France
              1. Filip de Keyser (filip.dekeyser{at}ugent.be)
              1. University Hospital Ghent, Belgium

                Abstract

                Background: Different methods exist to demonstrate anti-citrullinated protein/peptide antibodies (ACPA).

                Aims: To evaluate discrepancy between 4 ACPA tests.

                Patients and Methods: Population 1 consisted of patients with a new diagnostic problem including 86 RA and 450 non-RA patients. Population 2 consisted of 155 RA patients with longstanding disease. Population 3 consisted of 188 psoriatic arthritis (PsA) patients and population 4 consisted of 192 lupus (SLE) patients. Populations 1 and 2 were tested with the anti-human fibrinogen antibodies (AhfibA) test, anti-CCP2 from Eurodiagnostica (CCP2-euro), anti-CCP2 from Pharmacia (CCP2-phar) and anti-CCP3 test by Inova (CCP3). Samples were annotated as discrepant if positive in one and negative in at least one other test. Each discrepant sample was re-analyzed in a different run. Populations 3 and 4 were analyzed in the CCP2-euro and AhFibA test.

                Results: In population 1, ACPA positivity was found in 17 of 450 (3.8%) non-RA patients. 14 (82%) of those 17 samples were discrepant. In contrast, 61 (70.9%) of 86 RA patients were ACPA positive of whom 18 (29.5%) out of 61 were discrepant (70.9% vs. 29.5%, p<0.001). The discrepancies between tests could be partly attributed to borderline results, inter-assay discrepancy and inter-test variability. They were more prevalent in ACPA positive SLE patients than in ACPA positive PsA patients.

                Conclusions: Discrepancy between different ACPA tests was observed attributable to the occurrence of borderline results, inter-assay variability and mainly to inter-test variability. The lowest inter-test discrepancy is observed between tests that use the same substrate.

                • anti-citrullinated protein/peptide antibodies
                • discrepancy
                • rheumatoid arthritis

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.